STOCK TITAN

GoodRx (GDRX): Vanguard disaggregates holdings after Jan 12, 2026 realignment

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately.

The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

Does The Vanguard Group own any GoodRx (GDRX) shares per this filing?

No. The Schedule 13G/A amendment states The Vanguard Group beneficially owns 0 shares (0%) of GoodRx Common Stock as of the filing date shown in the amendment.

Why does Vanguard report separate holdings in this Schedule 13G/A for GDRX?

The filing explains Vanguard completed an internal realignment on January 12, 2026, and under SEC Release No. 34-39538 certain subsidiaries now report beneficial ownership separately from The Vanguard Group, Inc.

Who signed the Schedule 13G/A amendment for Vanguard on GoodRx (GDRX)?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/27/2026, certifying the information in the filing.

Does the filing identify any entity holding more than 5% of GoodRx common stock?

No. The Schedule 13G/A states that no one other person's interest in the securities reported herein is more than 5%, and Vanguard reports ownership of 5 percent or less of the class.

What address is listed for The Vanguard Group in the GoodRx Schedule 13G/A?

The filing lists The Vanguard Group's principal business office as 100 Vanguard Blvd., Malvern, PA 19355, as provided in the Schedule 13G/A amendment.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026